US Airline Sector 2026

The U.S. airline sector in early 2026 is the product of two overlapping cycles. The first is the post-COVID recovery wave: a violent rebound in demand, especially leisure and international, that allowed the big carriers to refill their cash tanks, repair balance sheets and renegotiate labor. The second is the return of classic airline constraints: high capital intensity, structurally volatile fuel costs, periodic labor shocks and the need to keep debt under control without sacrificing network relevance.

SHPH Shuttle Pharmaceuticals Holdings Inc

The 2026 biotech landscape is increasingly bifurcated between traditional development stories and “tech-bio” platforms that use AI to de-risk and compress timelines. Shuttle Pharmaceuticals positions itself at this intersection: a small oncology company built around radiosensitizers and a newly acquired AI platform, Molecule.ai, targeting the problem of radio-resistant tumors and inefficient drug development.

CRVS Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is a clinical-stage biotech now almost entirely defined by soquelitinib, an oral, highly selective ITK inhibitor designed to “rebalance” T-cell responses. The drug sits at the intersection of two very different but complementary franchises: inflammatory skin disease (atopic dermatitis) and T-cell lymphomas (PTCL and related entities).

IBRX ImmunityBio

Over the last few weeks ImmunityBio has done pretty much everything a biotech can do to light up screens: big revenue jump, new regulatory approvals and sexy cell-therapy data. The stock has reacted exactly the way you would expect in a heavily shorted name – vertical move, news sites still talking about it days later, social media on fire.

In this piece we are going to do something boring but necessary: stack all the verifiable positives (with links), then put them next to the very real risks. Only at the end we’ll talk about the “everybody is still pushing this story” part and why that’s exactly the moment when you want to cool your head.

Novocure’s TRIDENT Miss: Why the Glioblastoma Setback Matters for the $NVCR Pipeline

Novocure Ltd. TRIDENT Miss ripristina la storia del pipeline TTFields.

Novocure’s Phase 3 TRIDENT study did not show a statistically significant overall-survival advantage for starting Tumor Treating Fields earlier during chemoradiation in newly diagnosed glioblastoma. The result is not a collapse of the TTFields platform, but it is a serious reset for the near-term narrative: the company must now prove that its growth story can be carried by commercial execution, pancreatic cancer, brain metastases from NSCLC, and the next wave of combination trials.

ATOS Atossa Therapeutics Inc

Atossa Therapeutics is a small-cap, clinical-stage biotech built around a single platform asset, the oral selective estrogen receptor modulator (SERM) (Z)-endoxifen. Until 2025 the investment story was mostly about breast cancer treatment and risk reduction, but in the last few months the company has opened a new front in Duchenne muscular dystrophy (DMD).

OGN Organon & Co

The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division.

NVAX Novavax Inc at JPM CC

Why this NVAX update after JPM 2026
Novavax is a rare case where the narrative matters almost as much as the numbers. The company went from “late Covid vaccine laggard” to “maybe dead”, then back to life thanks to a sequence of deals and restructurings. The 44th J.P. Morgan Healthcare Conference was the moment where CEO John Jacobs tried to lock in a new story: Novavax as a lean, partner-driven, Matrix-M platform company with a visible (not guaranteed) path to sustainability.

ONDS Ondas Holdings Inc update jan 17

Why it is a “stock of the moment”
ONDS is one of the most closely watched names in the community: explosive rally, very strong narrative around Israel/defense, and now an Investor Day that pushes the bar even higher with 2026 guidance and very aggressive 5-year targets. It is a classic case where enthusiasm and risk coexist: great to follow, dangerous to underestimate.

POET Technologies Inc

This article is the natural continuation of the analysis published on January 3, 2026 on Merlintrader. Since then, POET has gone through a very busy few weeks: a strong share price move, intense options activity, fresh buzz around AI photonics, the long shadow of Marvell’s acquisition of Celestial AI, and a stream of unconfirmed rumours in retail communities.

IBRX – CGON – ENGN – NMIBC bladder-sparing race

igh-risk non-muscle-invasive bladder cancer after failure of BCG has become one of the hottest oncology niches of 2025–2026. ImmunityBio with ANKTIVA is already on the market, while CG Oncology and enGene are coming fast with late-stage programs. This report compares mechanisms, clinical data, timelines and sentiment, so traders can look beyond the single name that is dominating the headlines in these weeks.

ASND Ascendis Pharma

Achondroplasia already has one FDA-approved therapy on the market (BioMarin’s Voxzogo), so TransCon CNP is a “second entrant” story. That means the regulatory decision matters, but so will positioning, differentiation, and adoption post-approval.

JFBR Jeffs Brands Ltd

Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story.

OCUL Ocular Therapeutix Inc

Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk.

IBRX ImmunityBio Inc Update jan 14

Deep-dive update on ImmunityBio after the Saudi Food and Drug Authority granted approval to ANKTIVA + BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, on top of existing approvals in the U.S., U.K. and conditional approval in the EU. Focus on the non-muscle invasive bladder cancer franchise, commercial trajectory, balance sheet and the next catalysts around QUILT-3.032 and QUILT-2.005.